Altimmune (ALT) Expected to Announce Quarterly Earnings on Thursday
Altimmune (NASDAQ:ALT) is scheduled to release its Q4 2025 earnings before market open on Thursday, February 26th, with analysts anticipating a loss of ($0.25) per share. Recent insider activity includes two directors purchasing 12,500 shares each in December, and institutional investors collectively hold 78.05% of the company's stock. Despite mixed Wall Street sentiment, with six Buy ratings and an average price target of $17.60, the consensus rating for ALT is "Hold."
Altimmune, Inc. (ALT) Gains Analyst Support as Pemvidutide Advances
Altimmune, Inc. (ALT) has garnered analyst support, with Titan Partners initiating coverage with a Buy rating and a $7 target, citing promising Phase II results for its drug pemvidutide. The company recently completed a direct offering, raising $75 million for an upcoming Phase 3 trial of pemvidutide, which has received Breakthrough Therapy Designation for MASH. Despite Evercore ISI cutting its price target, the firm remains confident in Altimmune's long-term prospects due to pemvidutide's potential.
Altimmune, Inc. (NASDAQ:ALT) Given Average Rating of "Moderate Buy" by Brokerages
Ten brokerages have assigned an average "Moderate Buy" rating to Altimmune, Inc. (NASDAQ:ALT), with a consensus 12-month price target of $17.17, significantly higher than its current $4.65 share price. Recent insider buying activity includes two directors purchasing 12,500 shares each, and the company exhibits strong liquidity and low leverage. Institutional investors hold approximately 78% of the stock.
Altimmune, Inc. Closes $75 Million Registered Direct Offering to Advance Pemvidutide Development for Liver Diseases
Altimmune, Inc. successfully closed a registered direct offering, raising approximately $75 million. The funds will primarily support the upcoming Phase 3 trial of pemvidutide, a dual-action therapy for metabolic dysfunction-associated steatohepatitis (MASH), which recently received Breakthrough Therapy Designation from the FDA. This capital infusion is intended to strengthen Altimmune's financial position and enhance its strategic capabilities.
Altimmune, Inc. (ALT) gains analyst support ahead of phase 3 MASH development
This article states that Altimmune, Inc. (ALT) has garnered analyst support as it prepares for Phase 3 development of its MASH (Metabolic Dysfunction-Associated Steatohepatitis) drug candidate. The positive sentiment from analysts suggests confidence in the company's prospects in this therapeutic area.
Altimmune, Inc. (ALT) Gains Analyst Support Ahead of Phase 3 MASH Development
Altimmune, Inc. (ALT) has gained analyst support, with Barclays initiating coverage with an Overweight rating and a $20 price target, citing strong fundamentals and pipeline potential. The company plans to use recent offering proceeds to fund its Phase 3 MASH research for pemvidutide, a dual agonist described as a novel treatment. Despite the positive outlook for ALT, the article suggests that certain AI stocks may offer even greater and quicker returns.
Altimmune secures $75m for Phase 3 liver therapy trials
Altimmune has secured $75 million in a direct stock offering to fund Phase 3 trials for its lead therapy, pemvidutide, aimed at treating metabolic dysfunction-associated steatohepatitis (MASH) and other liver and metabolic diseases. Pemvidutide is notable for its duel action of reducing liver fat, inflammation, and scarring, while also regulating metabolism and promoting weight loss. The funding and Breakthrough Therapy Designation from the FDA highlight the therapy's potential to transform care for these conditions and offer a comprehensive approach to healthspan extension.
Altimmune closes $75 million registered direct offering By Investing.com
Altimmune, Inc. (NASDAQ:ALT) has successfully closed a $75 million registered direct offering, selling over 17 million shares or pre-funded warrants to an institutional investor. The biopharmaceutical company plans to use the proceeds to fund a pivotal Phase 3 trial for its MASH drug, pemvidutide, which recently received Breakthrough Therapy Designation from the FDA. Despite strong financial positioning, analysts do not expect Altimmune to be profitable this year and forecast continued sales decline.
Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock
Altimmune, Inc. successfully closed a $75 million registered direct offering of common stock with a new institutional investor. The proceeds from this offering will be allocated towards funding the upcoming Phase 3 trial for pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH), as well as for general working capital and corporate purposes. This strategic financial move aims to strengthen Altimmune's balance sheet and enhance its operational flexibility, particularly after receiving Breakthrough Therapy Designation for pemvidutide from the U.S. FDA.
Altimmune, Inc. (ALT) Stock Analysis: Exploring a 246% Potential Upside in the Biotech Arena
Altimmune, Inc. (ALT) is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic, and liver diseases, with its lead candidate, pemvidutide, in Phase 3 trials. Analysts project a potential upside of 246.41% despite the company's current negative P/E ratio and lack of revenue, common for early-stage biotech firms. The analysis highlights the high-risk, high-reward nature of Altimmune, supported by optimistic analyst sentiment and bullish technical indicators.
Altimmune closes $75 million registered direct offering
Altimmune, Inc. has successfully closed a $75 million registered direct offering. The biopharmaceutical company plans to use the proceeds to fund its upcoming Phase 3 trial for pemvidutide, a drug candidate for MASH, and for general corporate purposes. Despite a strong financial position, analysts do not expect the company to be profitable this year.
Biotech Altimmune raises $75M for Phase 3 MASH liver drug trial
Altimmune (Nasdaq: ALT) has successfully closed a registered direct offering, raising approximately $75 million to fund its planned Phase 3 pemvidutide trial for MASH, along with working capital and general corporate purposes. This financing follows positive Phase 2b data and an FDA Breakthrough Therapy Designation for pemvidutide, a dual-action therapy for serious liver diseases. The offering involved the sale of 17,045,454 shares of common stock or pre-funded warrants, which are immediately exercisable at $0.001 per share.
Altimmune, Inc. Closes $75 Million Registered Direct Offering to Advance Pemvidutide Development for Liver Diseases
Altimmune, Inc. has successfully closed a registered direct offering, raising approximately $75 million to fund the Phase 3 trial of its drug pemvidutide. This therapy, which recently received Breakthrough Therapy Designation from the FDA, is aimed at treating metabolic dysfunction-associated steatohepatitis (MASH). The offering is expected to enhance Altimmune's financial stability and strategic capabilities as it advances pemvidutide development.
Altimmune stock falls after announcing $75 million direct offering
Altimmune Inc (NASDAQ:ALT) stock dropped 6.2% in premarket trading after announcing a $75 million registered direct offering. The biopharmaceutical company plans to sell over 17 million shares to an institutional investor, with proceeds earmarked for its upcoming Phase 3 trial for pemvidutide, a MASH treatment that recently received Breakthrough Therapy Designation, and for general corporate purposes. This decline is attributed to market reaction to share dilution from the new equity offering.
Altimmune shares slide after $75 million registered direct offering
Altimmune (NASDAQ: ALT) announced a registered direct offering of 7.15 million shares at $10.50 each, aiming to raise $75 million. The offering includes warrants to purchase up to 7.15 million additional shares, exercisable at $12.00 per share. Following the announcement, Altimmune's stock dropped over 17% in premarket trading.
Altimmune raises $75 million to fund MASH therapy development By Investing.com
Altimmune, Inc. has raised approximately $75 million through a direct offering of common stock or pre-funded warrants to fund the development of its MASH therapy, pemvidutide. The company plans to use the proceeds for its upcoming Phase 3 trial and for general corporate purposes. Pemvidutide recently received Breakthrough Therapy Designation from the U.S. FDA, and Altimmune maintains a strong financial position with a market capitalization of $673.49 million and more cash than debt.
Altimmune Announces $75 Million Registered Direct Equity Offering
Altimmune (ALT) has announced a registered direct offering valued at $75 million, involving the sale of common stock and pre-funded warrants to a new institutional investor. The offering, expected to close around January 29, 2026, includes lock-up agreements for insiders and aims to secure additional funding for the biopharmaceutical company. Spark, TipRanks’ AI Analyst, currently assesses ALT as Neutral due to weak financial performance, despite positive clinical progress.
Altimmune Signs Multiple Material Agreements
Altimmune announced two material agreements, including a Securities Purchase Agreement with a new institutional investor for a registered direct offering to raise approximately $75 million, impacting 12,397,920 common shares and pre-funded warrants. The company also engaged Titan Partners Group as the sole placement agent for this offering, with closing anticipated around January 29, 2026. Directors and executives have agreed to 30-day lock-ups, and the pre-funded warrants are immediately exercisable with ownership limits.
Altimmune (ALT) Shares Slide On $75 Million Stock Offering
Altimmune (NASDAQ: ALT) shares fell sharply after the company announced a $75 million registered direct offering of common stock. The offering, priced at approximately $4.40 per share, aims to fund preparations for its upcoming Phase 3 trial in MASH for its drug Pemvidutide and for general corporate purposes. Despite a recent decline, the stock shows short-term strength but is in overbought territory, suggesting a potential correction.
Altimmune Stock Volatility Spurs Investor Attention
Altimmune Inc. (NASDAQ: ALT) has seen its stock drop by 11.57% due to investor concerns about its financial performance and aggressive expenditure without yielding positive results. Despite significant R&D investments and a strong balance sheet with $61M in cash reserves, the company reported a net loss of nearly $19M and a pretax profit margin of -6,149.7%. The volatility reflects wavering investor confidence awaiting strategic shifts and tangible revenue breakthroughs from its R&D efforts.
Altimmune stock falls after announcing $75 million direct offering By Investing.com
Altimmune Inc. (NASDAQ:ALT) stock dropped 6.2% in premarket trading after the biopharmaceutical company announced a $75 million registered direct offering. The offering involves selling over 17 million shares to an institutional investor, with proceeds funding preparation for a Phase 3 trial of pemvidutide for MASH and for general corporate purposes. This stock decline is a typical market reaction to share dilution from new equity offerings.
Altimmune Secures $75M from Institutional Investor in Direct Offering
Altimmune has secured approximately $75 million through a registered direct offering with a new institutional investor, selling 17.05 million shares. The funds will primarily support preparations for its upcoming Phase 3 trial in metabolic dysfunction-associated steatohepatitis, as well as general corporate purposes. Following the announcement, Altimmune's stock experienced a 3% rise in after-market trading, reflecting positive market sentiment, and analysts maintain a bullish outlook with an average 1-year price target of $13.00.
Altimmune raises $75 million to fund MASH therapy development
Altimmune, Inc. (NASDAQ:ALT) has successfully raised $75 million through a registered direct offering to an institutional investor. The funds are earmarked for preparing the Phase 3 trial of pemvidutide, its MASH therapy, and for general corporate purposes. Pemvidutide recently received Breakthrough Therapy Designation from the FDA, boosting the company's stock performance which saw a 33.77% gain over the past week and 71.19% year-to-date.
Altimmune, Inc. Announces $75 Million Registered Direct Offering to Support Phase 3 Trial for Pemvidutide
Altimmune, Inc. announced a $75 million registered direct offering through a securities purchase agreement with a new institutional investor. The offering of 17,045,454 shares aims to fund the preparation for a Phase 3 trial of its lead candidate, pemvidutide, for treating metabolic dysfunction-associated steatohepatitis (MASH). Pemvidutide has received Breakthrough Therapy Designation from the FDA, and the offering is expected to close around January 29, 2026.
Biotech Altimmune raises $75M to prepare Phase 3 MASH liver trial
Altimmune (Nasdaq: ALT) announced a registered direct offering to raise approximately $75 million through the sale of common shares or pre-funded warrants. The proceeds will be used to fund preparations for its upcoming Phase 3 trial for pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH), as well as for working capital and general corporate purposes. The company's pemvidutide previously received Breakthrough Therapy Designation from the U.S. FDA, supported by positive 48-week Phase 2b data.
Altimmune stock falls after announcing $75 million direct offering By Investing.com
Altimmune Inc. (NASDAQ:ALT) stock dropped over 6% in premarket trading after the biopharmaceutical company announced a $75 million direct offering of nearly 17.05 million shares to an institutional investor. The company plans to use the proceeds to fund its upcoming Phase 3 trial for pemvidutide, a MASH treatment that recently received FDA Breakthrough Therapy Designation. The stock decline is a typical market reaction to share dilution despite the advancement of its drug pipeline.
Evercore ISI lowers Altimmune stock price target to $22 from $25 By Investing.com
Evercore ISI has trimmed its price target for Altimmune (NASDAQ:ALT) to $22 from $25, while maintaining an Outperform rating. The adjustment comes after a comprehensive model overhaul, even as Altimmune's pemvidutide, a GLP-1/Glucagon drug, received Breakthrough Therapy Designation for MASH and showed promising 48-week trial data including continued weight loss and fibrosis improvement trends. The company also announced a leadership transition with CEO Vipin Garg stepping down by January 2026, to be replaced by current Chairman Jerry Durso.
Altimmune (ALT) Valuation Check After Pemvidutide’s FDA Breakthrough Therapy Designation
Altimmune (ALT) has gained significant attention after its lead candidate, pemvidutide, received FDA Breakthrough Therapy Designation for MASH, based on promising mid-stage trial data. Despite a recent surge in share price, the stock's one-year and five-year returns show a decline, leading to questions about whether the current optimism is an entry point or if future growth is already priced in. Analysts currently peg Altimmune's fair value at $28.00, suggesting it is significantly undervalued, contingent on successful upcoming data and regulatory milestones.
Altimmune (ALT) Shares Slide On $75 Million Stock Offering
Altimmune (ALT) shares fell following the announcement of a $75 million registered direct stock offering. The company plans to use the net proceeds to fund preparations for its upcoming Phase 3 trial in MASH (metabolic dysfunction-associated steatohepatitis) for its drug Pemvidutide. Despite some short-term strength indicators, the stock's RSI suggests it may be in overbought territory, potentially leading to a correction.
Altimmune (ALT) Is Up 29.7% After FDA Breakthrough Tag for Pemvidutide in MASH Trial
Altimmune (ALT) received FDA Breakthrough Therapy Designation for its drug pemvidutide for MASH treatment, following positive mid-stage data. This designation is expected to accelerate regulatory processes and bolster pemvidutide's standing in the competitive market. The company plans a 52-week late-stage trial, and this development significantly impacts Altimmune's investment narrative, with the stock seeing a nearly 30% increase.
Altimmune Stock Surges After FDA Breakthrough for MASH Therapy
Altimmune Inc. (NASDAQ: ALT) stock surged by 7.34% following the FDA's Breakthrough Therapy Designation for its MASH drug, pemvidutide. This designation, combined with positive Phase 2b trial results, accelerates the drug's path to market and significantly boosts investor confidence. The company plans for a Phase 3 trial aiming for accelerated approval, reinforcing its position in the competitive pharmaceutical industry despite current negative pretax profit margins and high R&D costs.
Stock Traders Purchase High Volume of Call Options on Altimmune (NASDAQ:ALT)
Altimmune (NASDAQ:ALT) experienced unusually high call option trading volume on Friday, with 14,727 call options acquired, a 63% increase from the average. This coincided with an 11.3% jump in the stock price to $5.99 on heavy trading. Insider activity included directors John Gill and Jerome Benedict Durso purchasing 12,500 shares each in December at around $4.10, indicating increased insider ownership.
Altimmune (ALT) Receives FDA Breakthrough Therapy Designation, Shares Rise Nearly 4%
Altimmune (ALT) received FDA Breakthrough Therapy Designation for its drug pemvidutide, based on positive mid-stage trial data for MASH resolution, which is expected to accelerate its development. This news led to a nearly 4% rise in Altimmune's shares, reflecting renewed investor confidence. The company is poised to initiate late-stage trials and has a strong financial position, potentially opening doors for collaborations or acquisition.
Altimmune, Inc. (NASDAQ:ALT) Receives Consensus Recommendation of "Hold" from Analysts
Altimmune, Inc. (NASDAQ:ALT) has received a consensus "Hold" recommendation from analysts, with nine firms providing ratings: two "sell," one "hold," and six "buy." The average 12-month price target is $16.60, significantly higher than its current trading price of approximately $4.24. Recent insider purchases by directors and substantial institutional investor activity, including large buys by Vanguard and Two Sigma, suggest some confidence despite the company's negative profitability metrics and P/E ratio.
Altimmune’s Promising Drug Candidate Fuels Analyst Confidence
Altimmune continues to receive positive analyst sentiment due to the clinical progress of its drug candidate, Pemvidutide, for MASH. The drug has received FDA Breakthrough Therapy designation, and analysts project significant upside with an average price target of $16.33 to $19.00 against the current trading price of $4.24, even though the company reported a net loss in Q3 2025. Insider stock purchases also suggest confidence, and the company is preparing for a pivotal Phase 3 program in late 2026, targeting a specific niche in a competitive market.
Altimmune receives FDA’s breakthrough therapy designation for its liver disease drug
Altimmune has received Breakthrough Therapy designation from the FDA for its drug, pemvidutide, aimed at treating metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease. This designation will expedite the development and review process for the drug, recognizing its potential to offer significant improvements over existing therapies. Pemvidutide has shown promising results in clinical trials, targeting key aspects of MASH and fibrosis.
Can Altimmune's Pemvidutide Follow In The Footsteps Of Rezdiffra And Wegovy In The MASH Landscape?
Altimmune Inc. is developing Pemvidutide, a dual-action therapy for Metabolic dysfunction-associated steatohepatitis (MASH), building on positive 48-week phase 2b trial data. The drug, which targets glucagon and GLP-1, showed significant improvements in liver fibrosis and inflammation markers. Altimmune plans to advance Pemvidutide into a phase 3 study this year, also exploring its potential for Alcohol Use Disorder and Alcohol-associated Liver Disease.
Can Altimmune's Pemvidutide Follow In The Footsteps Of Rezdiffra And Wegovy In The MASH Landscape?
Altimmune Inc. is developing Pemvidutide, a dual-action therapy for metabolic dysfunction-associated steatohepatitis (MASH), building on the success of FDA-approved drugs like Rezdiffra and Wegovy. The company announced positive 48-week data from its phase 2b IMPACT trial, showing significant improvements in liver fibrosis and inflammation markers, along with continued weight loss and a favorable tolerability profile. Altimmune plans to advance Pemvidutide into a phase 3 study this year and is also exploring its use for Alcohol Use Disorder and Alcohol-associated Liver Disease.
Altimmune’s pemvidutide earns FDA breakthrough status
Altimmune's pemvidutide has received Breakthrough Therapy Designation from the FDA for treating MASH. This designation highlights the therapy's potential to significantly improve outcomes for a disease with limited treatment options by addressing both metabolic dysfunction and liver damage. The move is based on positive Phase 2b trial data showing MASH resolution without fibrosis worsening and a favorable safety profile, potentially accelerating its path to market.
Wayne Pisano Acquires 5,000 Shares of Altimmune (NASDAQ:ALT) Stock
Director Wayne Pisano recently acquired 5,000 shares of Altimmune (NASDAQ:ALT) stock for $20,400, increasing his direct stake to 13,498 shares. Despite the purchase, Altimmune remains unprofitable with significant liquidity ratios, and its shares dropped by 1.5%. Analyst sentiment is split, with a consensus "Hold" rating and a target price of $16.60, while institutional investors hold a substantial portion of the company's stock.
Insider Move: Altimmune Director Makes Bold New Stock Purchase
Altimmune director Wayne Pisano recently purchased 5,000 shares of Altimmune stock for $20,400, signaling confidence despite recent share volatility. The company's lead drug, pemvidutide, has shown positive Phase 2b MASH data and received FDA Breakthrough Therapy Designation, but faces financial challenges and competition. TipRanks' AI Analyst, Spark, rates ALT as Neutral due to weak financial performance partially offset by clinical and regulatory momentum.
FDA grants breakthrough therapy status to Altimmune’s MASH drug
Altimmune, Inc. (NASDAQ:ALT) announced that the FDA has granted Breakthrough Therapy Designation for its drug pemvidutide, targeting metabolic dysfunction-associated steatohepatitis (MASH). This designation, based on positive Phase 2b trial data, aims to accelerate the drug's development and review. The company is now planning a Phase 3 trial and has recently seen a leadership transition, with Jerry Durso succeeding Vipin Garg as CEO.
Altimmune (ALT) Is Up 16.1% After FDA Breakthrough Nod For AI-Enhanced MASH Drug Trial – Has The Bull Case Changed?
Altimmune (ALT) experienced a 16.1% stock increase following the FDA's Breakthrough Therapy Designation for its MASH drug, pemvidutide, based on positive Phase 2b trial data. The upcoming Phase 3 trial will utilize AIM-MASH AI Assist, an FDA-qualified AI pathology tool. This designation strengthens Altimmune's investment narrative around pemvidutide, potentially shortening timelines for regulatory approval, though the company still faces single-asset concentration risk and reliance on equity financing.
Altimmune (ALT) Is Up 16.1% After FDA Breakthrough Nod For AI-Enhanced MASH Drug Trial – Has The Bull Case Changed?
Altimmune (ALT) experienced a 16.1% stock increase after its drug, pemvidutide, received FDA Breakthrough Therapy Designation for MASH, leveraging AI technology in its Phase 3 trial. This strengthens the investment narrative for the company by potentially accelerating timelines and validating its MASH platform, despite existing risks related to single-asset concentration and financial uncertainties. The company's valuation remains a point of varying opinions among investors.
ALT Stock Up 17% After Pemvidutide Gets FDA Breakthrough Tag for MASH
Altimmune's stock (ALT) surged 17% after its lead candidate, pemvidutide, received FDA Breakthrough Therapy Designation for metabolic dysfunction-associated steatohepatitis (MASH). This designation is based on positive phase IIb IMPACT study data showing significant MASH resolution and improvements in liver health. The company plans to advance pemvidutide into a phase III study in 2026, with the drug also being developed for alcohol use disorder and alcohol-associated liver disease.
Altimmune’s Surprising Stock Surge: What’s Behind It?
Altimmune Inc. (NASDAQ: ALT) experienced a significant stock surge of 23.33% following positive topline results from its Phase 2b trial for pemvidutide in MASH patients, which included notable improvements in liver tests and weight loss. While the company faces financial challenges, strong liquidity and FDA backing for a Phase 3 trial are contributing to investor optimism. The market's reaction highlights the balance between promising medical advancements and the need for robust financial performance for sustained growth.
Altimmune, GH Research, Gyre Therapeutics And Other Big Stocks Moving Higher On Monday
U.S. stocks saw broad gains on Monday, with the Dow Jones index climbing over 500 points. Several companies experienced significant surges, driven by positive news. Key movers include Altimmune Inc, which rose sharply after receiving FDA Breakthrough Therapy Designation for Pemvidutide, and GH Research PLC, which gained following the FDA lifting a clinical hold on its IND for GH001.
Altimmune stock gains on FDA breakthrough status (ALT:NASDAQ)
Altimmune's stock surged approximately 19% in premarket trading after the U.S. FDA granted Breakthrough Therapy Designation for its drug, pemvidutide. This designation is for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), a significant liver disorder.
FDA flags new liver disease drug for faster review after promising early data
Altimmune (NASDAQ: ALT) announced that the FDA granted Breakthrough Therapy Designation for pemvidutide to treat metabolic dysfunction-associated steatohepatitis (MASH) based on promising Phase 2b data. This designation will expedite the drug's development and review process, aiming to address significant unmet medical needs. Following the announcement, Altimmune's stock saw a significant positive market reaction, increasing by 14.53%.
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH
Altimmune, Inc. announced that the FDA has granted Breakthrough Therapy Designation (BTD) for pemvidutide, their balanced glucagon/GLP-1 dual receptor agonist, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). This designation is based on positive Phase 2b trial data showing significant MASH resolution and improvements in liver health indicators. The company plans to initiate a Phase 3 trial, aligning with FDA parameters, to further evaluate pemvidutide's potential for accelerated approval in MASH.
